Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail
Driven by a series of wins for its antibody-drug conjugate pipeline, Daiichi Sankyo has earned a reputation as an ADC expert with a successful partnership with AstraZeneca under its belt. But failures do happen — and for Daiichi, it’s where the company least expected it.
Daiichi has scrapped development of DS-6157, an ADC targeting the GPR20 protein in gastrointestinal stromal tumors (GIST), after the drug failed a Phase I test, the drugmaker revealed in its Q2 update Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.